Overview

A Study to Test BI 655130 in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis

Status:
Completed
Trial end date:
2021-01-05
Target enrollment:
Participant gender:
Summary
To evaluate efficacy, safety, and tolerability of BI 655130 compared to placebo in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.
Phase:
Phase 2
Details
Lead Sponsor:
Boehringer Ingelheim